eligibility_summary
Patients: Post haplo or matched HCT with CMV/ADV viremia refractory (persistent ≥14d or ≥1 log rise ≥7d), no GVHD, haplo donor available, no DLI <4wk, consent, adequate cardiac/hepatic/renal/pulmonary function, limited diarrhea, engrafted ANC>500×3d. Donors: ≥18, ≥3/6 haplo family, HIV−, not pregnant/lactating, 21 CFR eligible. Exclude: GVHD, pregnancy, no consent, pressors/vent, steroids>0.5 mg/kg, DLI<4wk, ATG/Alem<30d, uncontrolled infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Interventions: VST infusion—single IV dose of allogeneic, haploidentical donor CMV- and adenovirus-specific T cells, manufactured by antigen stimulation and IFN-γ capture on the CliniMACS Prodigy. Type: adoptive cellular immunotherapy (biologic). Mechanism of action: transferred CD3+ virus-specific T cells (CD4+ and CD8+) recognize CMV/ADV peptides via TCR-HLA, secrete IFN-γ, and kill infected cells via perforin/granzyme, reconstituting antiviral immunity post-HCT. Targets: CMV- and adenovirus-infected host cells, immune pathways include TCR antigen recognition, IFN-γ signaling, and cytotoxic effector functions. Device (CliniMACS) enables selection, not therapeutic itself. Cohorts test donors identical vs different from the stem cell donor.